Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

about

Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.

P2860

Q35569714-03816F8A-4674-4BC8-8562-4CA23F0B91A8 Q38801590-74F77DA3-8129-4BBE-89C0-D3B1DA92763E

P2860

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

Item

http://www.wikidata.org/entity/Q38216215

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

@en

type

Item

label

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

@en

prefLabel

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

@en

P1476

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

@en

P2093

Marcello Marino

http://www.w3.org/2001/XMLSchema#string

P2860

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Clinical aspects of platelet inhibitors and thrombus formation

Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI

Bivalirudin during primary PCI in acute myocardial infarction

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

P2888

s11886-014-0493-4

P304

493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-014-0493-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sergio Leonardi

Diego Rizzotti

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004342886

http://www.w3.org/2001/XMLSchema#string

P698

24879371

http://www.w3.org/2001/XMLSchema#string

P921

cangrelor

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

about

P2860

P2860

Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921